BiologicalDrug
XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410 clinical trials
Also written PVX-410.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 2
Massachusetts General Hospital (2) · OncoPep, Inc. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410 is read from its arms, and is right about nine times in ten.
Testing it · 4
- PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1Massachusetts General HospitalNCT03362060Written as PVX-410
- Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerActive, not recruitingPhase 1Massachusetts General HospitalNCT02826434Written as PVX-410
- Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast CancerStatus unknownPhase 2OncoPep, Inc.NCT04634747Written as PVX-410
- Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple MyelomaCompletedPhase 1OncoPep, Inc.NCT01718899Written as PVX-410